Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Has Average Target Price of $41.50

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $41.50.

AGIO has been the topic of several analyst reports. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Citigroup increased their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Bank of America raised their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. JPMorgan Chase & Co. lifted their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Royal Bank Of Canada lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th.

Insider Activity

In related news, insider Sarah Gheuens sold 1,489 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $37.53, for a total transaction of $55,882.17. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $2,050,826.85. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 31,989 shares of company stock worth $989,042. Corporate insiders own 5.40% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Sei Investments Co. increased its position in Agios Pharmaceuticals by 342.8% in the 1st quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 49,198 shares during the period. SCS Capital Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $22,743,000. Parkman Healthcare Partners LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $24,828,000. Bank of America Corp DE acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $18,847,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $864,000.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $37.00 on Friday. The company’s fifty day moving average price is $33.41 and its two-hundred day moving average price is $32.79. The firm has a market capitalization of $2.21 billion, a P/E ratio of -5.28 and a beta of 0.63. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. On average, sell-side analysts anticipate that Agios Pharmaceuticals will post -5.83 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.